Suzy Jones is the Founder and Managing Partner of DNA Ink, a life sciences advisory firm in San Francisco. Prior to founding DNA Ink, Ms. Jones spent 20 years at Genentech in various roles in immunology research, product development and business development where she was Head of Non-Oncology Licensing and later Interim Head of Partnering and Head of Business Development. During this time, she managed Genentech’s CD20 portfolio of assets, including Rituxan, the first monoclonal antibody launched to treat cancer, Ocrevus and Gazyva. Ms. Jones served as a member of the board of directors of Calithera Biosciences (formerly NASDAQ listed) and Patrys Limited, (ASX listed) Australian. She received a B.A. in Biology from University of California, Santa Cruz.